EE04188B1 - Tetrahüdropüridiinderivaadi kristallisatsioonimeetod ja moodustuvad kristalsed vormid - Google Patents

Tetrahüdropüridiinderivaadi kristallisatsioonimeetod ja moodustuvad kristalsed vormid

Info

Publication number
EE04188B1
EE04188B1 EEP199900264A EE9900264A EE04188B1 EE 04188 B1 EE04188 B1 EE 04188B1 EE P199900264 A EEP199900264 A EE P199900264A EE 9900264 A EE9900264 A EE 9900264A EE 04188 B1 EE04188 B1 EE 04188B1
Authority
EE
Estonia
Prior art keywords
formation
crystalline forms
crystallization method
tetrahydropyridine derivative
tetrahydropyridine
Prior art date
Application number
EEP199900264A
Other languages
English (en)
Estonian (et)
Other versions
EE9900264A (et
Inventor
Caron Antoine
Franc Bruno
Monnier Olivier
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of EE9900264A publication Critical patent/EE9900264A/xx
Publication of EE04188B1 publication Critical patent/EE04188B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP199900264A 1996-12-23 1997-12-23 Tetrahüdropüridiinderivaadi kristallisatsioonimeetod ja moodustuvad kristalsed vormid EE04188B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (fr) 1996-12-23 1996-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
PCT/FR1997/002393 WO1998028271A1 (fr) 1996-12-23 1997-12-23 Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Publications (2)

Publication Number Publication Date
EE9900264A EE9900264A (et) 2000-02-15
EE04188B1 true EE04188B1 (et) 2003-12-15

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900264A EE04188B1 (et) 1996-12-23 1997-12-23 Tetrahüdropüridiinderivaadi kristallisatsioonimeetod ja moodustuvad kristalsed vormid

Country Status (39)

Country Link
EP (1) EP0950050B1 (zh)
JP (2) JP4499188B2 (zh)
KR (1) KR100586670B1 (zh)
CN (1) CN1129580C (zh)
AR (1) AR009672A1 (zh)
AT (1) ATE307802T1 (zh)
AU (1) AU736697B2 (zh)
BR (1) BR9714081A (zh)
CA (1) CA2275596C (zh)
CO (1) CO5070688A1 (zh)
CZ (1) CZ296689B6 (zh)
DE (1) DE69734460T2 (zh)
DK (1) DK0950050T3 (zh)
DZ (1) DZ2383A1 (zh)
EE (1) EE04188B1 (zh)
EG (1) EG21567A (zh)
ES (1) ES2251038T3 (zh)
FR (1) FR2757543B1 (zh)
HK (1) HK1024002A1 (zh)
HR (1) HRP970699B1 (zh)
HU (1) HU227425B1 (zh)
IL (1) IL129938A (zh)
IN (1) IN186976B (zh)
IS (1) IS2357B (zh)
MY (1) MY118015A (zh)
NO (1) NO312364B1 (zh)
NZ (1) NZ336130A (zh)
PL (1) PL190494B1 (zh)
RS (1) RS49882B (zh)
RU (1) RU2192416C2 (zh)
SA (1) SA98180971B1 (zh)
SI (1) SI0950050T1 (zh)
SK (1) SK285088B6 (zh)
TR (1) TR199901363T2 (zh)
TW (1) TW518322B (zh)
UA (1) UA60324C2 (zh)
UY (1) UY24825A1 (zh)
WO (1) WO1998028271A1 (zh)
ZA (1) ZA9711576B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues
FR2782082B3 (fr) * 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
WO2011111857A1 (ja) 2010-03-12 2011-09-15 株式会社日本触媒 吸水性樹脂の製造方法
ES2604405T3 (es) * 2011-04-15 2017-03-06 Emcure Pharmaceuticals Limited Un procedimiento para rilpivirina mejorado

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
HUP0001387A3 (en) 2002-03-28
CZ296689B6 (cs) 2006-05-17
KR100586670B1 (ko) 2006-06-07
CN1129580C (zh) 2003-12-03
DK0950050T3 (da) 2006-01-23
JP2001507012A (ja) 2001-05-29
RS49882B (sr) 2008-08-07
ZA9711576B (en) 1998-06-25
JP2009197022A (ja) 2009-09-03
EE9900264A (et) 2000-02-15
ES2251038T3 (es) 2006-04-16
YU28999A (sh) 2003-01-31
AR009672A1 (es) 2000-04-26
UA60324C2 (uk) 2003-10-15
DZ2383A1 (fr) 2002-12-28
HUP0001387A2 (hu) 2000-09-28
CA2275596C (en) 2005-10-11
DE69734460D1 (de) 2005-12-01
SK82899A3 (en) 1999-12-10
IS2357B (is) 2008-04-15
PL190494B1 (pl) 2005-12-30
HRP970699B1 (en) 2007-03-31
NO312364B1 (no) 2002-04-29
HU227425B1 (en) 2011-05-30
ATE307802T1 (de) 2005-11-15
FR2757543B1 (fr) 1999-04-02
MY118015A (en) 2004-08-30
IN186976B (zh) 2001-12-22
NO993076D0 (no) 1999-06-22
SA98180971B1 (ar) 2006-09-13
HRP970699A2 (en) 1998-10-31
EP0950050B1 (fr) 2005-10-26
CO5070688A1 (es) 2001-08-28
CZ229299A3 (cs) 1999-09-15
FR2757543A1 (fr) 1998-06-26
SK285088B6 (sk) 2006-06-01
AU5668498A (en) 1998-07-17
DE69734460T2 (de) 2006-07-06
KR20000069504A (ko) 2000-11-25
BR9714081A (pt) 2000-05-09
IS5076A (is) 1999-06-10
IL129938A (en) 2004-06-20
EP0950050A1 (fr) 1999-10-20
IL129938A0 (en) 2000-02-29
PL334256A1 (en) 2000-02-14
NO993076L (no) 1999-06-22
TW518322B (en) 2003-01-21
TR199901363T2 (xx) 1999-08-23
HK1024002A1 (en) 2000-09-29
NZ336130A (en) 2001-01-26
UY24825A1 (es) 1998-04-21
RU2192416C2 (ru) 2002-11-10
CA2275596A1 (en) 1998-07-02
WO1998028271A1 (fr) 1998-07-02
SI0950050T1 (sl) 2006-04-30
JP4499188B2 (ja) 2010-07-07
AU736697B2 (en) 2001-08-02
CN1241180A (zh) 2000-01-12
EG21567A (en) 2001-12-31

Similar Documents

Publication Publication Date Title
EE9400366A (et) Kristallilised metall- alfa- 2- interferoonid ja meetod nende valmistamiseks ning kristallilised alfa- 2- interferoonid
FI973750A0 (fi) 2-metyylitienobentsodiatsepiinin valmistus ja kiteiset muodot
BR9711151A (pt) Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
ATE238310T1 (de) Kristalline substanz von pivoxilcefditoren und verfahren zu ihrer herstellung
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
NO981434D0 (no) Fremgangsmåte for fremstilling av piperidinderivater
FI962464A (fi) Kiteisiä N-asetyyliamiinihappojohdannaisia ja menetelmiä niiden valmistamiseksi
KR100287082B1 (ko) 피페리딘디온유도체의입체특이적가수분해방법
NO990792D0 (no) FremgangsmÕte for inhibering av ekspresjonen av FAS
EE04188B1 (et) Tetrahüdropüridiinderivaadi kristallisatsioonimeetod ja moodustuvad kristalsed vormid
NO20010553L (no) Krystallinske former av osanetant
NO308471B1 (no) FremgangsmÕter for fremstilling av lorakarbefmonohydrat og krystallinsk anhydratform av lorakarbef
NO952668L (no) Fremgansmåte til fremstilling av N-alkyl-laktamer
IS2064B (is) Öragna form tetrahýdrópýrídínafleiðu
NO20004583D0 (no) Krystallinsk form av paroxetine
UA26019C2 (uk) Спосіб підготовки кристалу до обточуваhhя
BR9610201A (pt) Forma cristalina alternativa de tazofelona

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20111223